Kivu Bioscience is pioneering next-generation antibody-drug conjugates (ADCs) in oncology. The company's proprietary linker-payload technology delivers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. With multiple ADC programs in development and a team of industry veterans, Kivu is advancing its first two lead candidates to clinical trials expected to begin in 2025.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/28/24	$92,000,000	Series A	BioGeneration Ventures Brabantse Ontwikkelings Maatschappij GIMV HealthCap M Ventures Novo Holdings Red Tree Venture Captial	undisclosed